Hims & Hers Health (NYSE:HIMS) Shares Up 8.4% – Time to Buy?

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) were up 8.4% during mid-day trading on Monday . The company traded as high as $29.75 and last traded at $30.0910. 1,692,662 shares traded hands during mid-day trading, a decline of 94% from the average session volume of 27,293,625 shares. The stock had previously closed at $27.77.

Analyst Upgrades and Downgrades

HIMS has been the topic of several recent analyst reports. BTIG Research reaffirmed a “neutral” rating on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Zacks Research raised Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Wall Street Zen cut shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. UBS Group set a $23.00 price objective on shares of Hims & Hers Health in a report on Friday, May 22nd. Finally, Needham & Company LLC increased their target price on shares of Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Four analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Hims & Hers Health presently has a consensus rating of “Hold” and a consensus target price of $31.43.

Hims & Hers Health Price Performance

The business has a 50-day simple moving average of $31.23 and a two-hundred day simple moving average of $26.08. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The stock has a market capitalization of $7.03 billion, a price-to-earnings ratio of -338.17, a P/E/G ratio of 78.15 and a beta of 2.35.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The firm had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. During the same quarter last year, the business posted $0.20 earnings per share. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. As a group, research analysts predict that Hims & Hers Health, Inc. will post 0.03 earnings per share for the current fiscal year.

Insider Activity

In other Hims & Hers Health news, insider Irene Becklund sold 7,573 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $30.25, for a total value of $229,083.25. Following the completion of the sale, the insider directly owned 11,280 shares of the company’s stock, valued at approximately $341,220. This represents a 40.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Oluyemi Okupe sold 18,197 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $34.03, for a total transaction of $619,243.91. Following the transaction, the chief financial officer owned 284,321 shares of the company’s stock, valued at approximately $9,675,443.63. This trade represents a 6.02% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 83,126 shares of company stock valued at $2,711,339 over the last quarter. Insiders own 11.76% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in HIMS. Bank of America Corp DE increased its position in shares of Hims & Hers Health by 194.4% in the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock worth $90,465,000 after acquiring an additional 2,877,550 shares in the last quarter. Norges Bank purchased a new stake in shares of Hims & Hers Health in the 4th quarter valued at approximately $62,153,000. Invesco Ltd. boosted its stake in Hims & Hers Health by 62.7% in the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock worth $235,525,000 after purchasing an additional 1,600,004 shares during the period. Marex Group plc boosted its stake in Hims & Hers Health by 162.2% in the 4th quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock worth $78,562,000 after purchasing an additional 1,496,707 shares during the period. Finally, Vanguard Group Inc. grew its position in Hims & Hers Health by 7.2% during the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after purchasing an additional 1,407,651 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.